Audio & video media exploring relevant topics.
“These videos start with some short introductory information and lead up to the excellent 6th video by Dr. Jill James that connects many of the dots on methylation, neurotransmission, and a variety of neurodevelopmental issues from autism to ADHD.”
Methylation Details For Treatment Failure The CoreBrain Journal Walsh Molecular Series: 1 of 3 – Audio
“More than two-thirds of persons diagnosed with a behavior or mental disorder exhibit a methylation imbalance. A person’s methyl status is established during the first few months of in-utero development and this condition tends to persist throughout life.:
~ William Walsh
“Your gut and your brain are in constant communication, probably without you even knowing it. This gut-brain axis is essentially a bidirectional communication that occurs between the brain and the microbiota. Because of this and the fact that ¾ of your neurotransmitter production happens in the gut, mood disorders such as anxiety and depression have been linked back to a person’s gut health. Learn more about HOW what you eat, can cause anxiety and depression.”
“Gaining control of our minds, bodies, and life is what biohackers do in order to perform our best. In this show the notable Dr. William Walsh of the Walsh Research Institute uncovers the knowledge he’s gained after over 30 years of researching human biochemistry. You’ll hear about:
– Engineering the human chemistry,
– Trace metals,
– Dr. Walsh’s work with ex-convicts,
– The power of nutrients,
– Blood testing, and even Dr. Walsh’s theory on school shootings.”
Dr. Satchin Panda states that circadian rhythm fasting has many benefits. That the timing of when you eat is essential for your health. Benefits include reduced cholesterol levels, decreased risk of diabetes and obesity, less inflammation, and greater longevity, amongst other benefits.
“Advanced Nutrient Therapies for Bipolar Disorders with Dr. Walsh” – Natural Treatment for Bipolar – Video
“Our present dependence on psychiatric drugs will gradually fade away as brain science advances. Learn how brain-changing imbalances occur in bipolar disorder. Discover how these imbalances alter brain levels of key neurotransmitters, disrupt epigenetic regulation of synapse activity, and cripple the body’s protection against environmental toxins.”
Scientific published research exploring relevant topics.
Abstract: “Bipolar disorder is a serious mental illness characterized by alternating periods of elevated and depressed mood. Sleep disturbances in bipolar disorder are present during all stages of the condition and exert a negative impact on overall course, quality of life, and treatment outcomes. We examine the partnership between circadian system (process C) functioning and sleep-wake homeostasis (process S) on optimal sleep functioning and explore the role of disruptions in both systems on sleep disturbances in bipolar disorder. A convergence of evidence suggests that sleep problems in bipolar disorder result from dysregulation across both process C and process S systems. Biomarkers of depressive episodes include heightened fragmentation of rapid eye movement (REM) sleep, reduced REM latency, increased REM density, and a greater percentage of awakenings, while biomarkers of manic episodes include reduced REM latency, greater percentage of stage I sleep, increased REM density, discontinuous sleep patterns, shortened total sleep time, and a greater time awake in bed. These findings highlight the importance of targeting novel treatments for sleep disturbance in bipolar disorder.
Fasting, circadian rhythms, and time restricted feeding in healthy lifespan – Cell metabolism – 2016 Jun 14
Abstract: “Feeding in most animals is confined to a defined period, leaving short periods of fasting that coincide with sleep. Fasting enables organisms to enter alternative metabolic phases, which rely less on glucose and more on ketone body-like carbon sources. Both intermittent and periodic fasting result in benefits ranging from prevention to the enhanced treatment of diseases. Similarly, time-restricted feeding (TRF), in which feeding time is restricted to certain hours of the day, allows the daily fasting period to last >12 h, thus imparting pleiotropic benefits in multiple organisms. Understanding the mechanistic link between nutrients and the fasting benefits is leading to the identification of fasting mimicking diets (FMDs) that achieve changes similar to those caused by fasting. Given the pleiotropic and sustained benefits of TRF and FMD, both basic science and translational research are warranted to develop fasting-associated interventions into effective and inexpensive treatments with the potential to improve healthspan.”
Links between circadian rhythms and psychiatric disease – Frontiers in Behavioral Neuroscience – 2014 May 6
Abstract: “Determining the cause of psychiatric disorders is a goal of modern neuroscience, and will hopefully lead to the discovery of treatments to either prevent or alleviate the suffering caused by these diseases. One roadblock to attaining this goal is the realization that neuropsychiatric diseases are rarely due to a single gene polymorphism, environmental exposure, or developmental insult. Rather, it is a complex interaction between these various influences that likely leads to the development of clinically relevant syndromes. Our lab is exploring the links between environmental exposures and neurobehavioral function by investigating how disruption of the circadian (daily) clock alters the structure and function of neural circuits, with the hypothesis that disrupting this crucial homeostatic system can directly contribute to altered vulnerability of the organism to other factors that interact to produce psychiatric illness. This review explores some historical and more recent findings that link disrupted circadian clocks to neuropsychiatric disorders, particularly depression, mania, and schizophrenia. We take a comparative approach by exploring the effects observed in human populations, as well as some experimental models used in the laboratory to unravel mechanistic and causal relationships between disruption of the circadian clock and behavioral abnormalities. This is a rich area of research that we predict will contribute greatly to our understanding of how genes, environment, and development interact to modulate an individual’s vulnerability to psychiatric disorders.”
THE ROLE OF INFLAMMATION AND MICROGLIAL ACTIVATION IN THE PATHOPHYSIOLOGY OF PSYCHIATRIC DISORDERS – ResearchGate – 2015 May
Abstract: “Psychiatric disorders, including major depressive disorder (MDD), bipolar disorder (BD) and schizophrenia, affect a significant percentage of the world population. These disorders are associated with educational difficulties, decreased productivity and reduced quality of life, but their underlying pathophysiological mechanisms are not fully elucidated. Recently, studies have suggested that psychiatric disorders could be considered as inflammatory disorders, even though the exact mechanisms underlying this association are not known. An increase in inflammatory response and oxidative stress may lead to inflammation, which in turn can stimulate microglia in the brain. Microglial activation is roused by the M1 phenotype, which is associated with an increase in interleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a). On the contrary, M2 phenotype is associated with a release of anti-inflammatory cytokines. Thus, it is possible that the inflammatory response from microglial activation can contribute to brain pathology, as well as influence treatment responses. This review will highlight the role of inflammation in the pathophysiology of psychiatric disorders, such as MDD, BD, schizophrenia, and autism. More specifically, the role of microglial activation and associated molecular cascades will also be discussed as a means by which these neuroinflammatory mechanisms take place, when appropriate.”
Are Anti-inflammatory Therapies Viable Treatments for Psychiatric Disorders?: Where the Rubber Meets the Road – JAMA Psychiatry – 2017 Aug 3
Abstract: “Accumulating data indicate that inflammation may play a role in a host of psychiatric illnesses.1 These data reveal reliable associations of inflammatory markers with psychiatric disorders, the induction of psychiatric symptoms following administration of inflammatory stimuli, the association of inflammation-related genes with psychiatric disease, and the elucidation of neurobiological and immunological mechanisms by which inflammation targets neurotransmitters and neurocircuits to change behavior. Nevertheless, whether therapeutic strategies that inhibit inflammation will be effective in treating psychiatric illnesses remains unclear. This question is not trivial given the pressing need for novel therapeutics based on the high rates of treatment resistance across disorders and on our relatively limited psychopharmacologic repertoire.
As reflected in recent reviews of the efficacy of anti-inflammatory drugs in treating depression and schizophrenia, including a recent meta-analysis on depression published in JAMA Psychiatry,2 the experimental strategies used to date are the ones that have failed to yield new drugs for psychiatric disorders. Clinical trials using anti-inflammatory agents with multiple off-target effects on nonselected populations of patients, using nonspecific measures of outcome without evidence of target engagement, provide limited information and run the risk of repeating an approach that, although familiar, is no longer viable. It is this very approach that has led the National Institute of Mental Health to demand more rigorous standards regarding clinical trials, including an “experimental medicine” approach to avoid the mistakes of the past.3 In the case of inflammation, these mistakes are being repeated despite the existence of a treasure trove of data that can inform future studies and ultimately determine whether inhibiting inflammation holds therapeutic promise. A brief evaluation of what we know and how it can guide future study design is a necessary first step toward making this determination. The following tenets are proffered as initial guideposts to address the challenge.”
Abstract: “Schizophrenia and bipolar disorder are serious neuropsychiatric disorders of uncertain etiology. Recent studies indicate that immune activation may contribute to the etiopathogenesis of these disorders. Numerous studies in animal models indicate that the mucosal microbiome may influence cognition and behavior by altering the functioning of the immune system. It is thus likely that the microbiome plays a role in human psychiatric disorders. The study of immune alterations and the microbiome in schizophrenia and bipolar disorder is in its infancy. Two recent investigations of the oro-pharyngeal microbiota in schizophrenia found differences between cases and controls. Other studies have found increased gastrointestinal inflammation in schizophrenia and bipolar disorder based on measures of microbial translocation. Several studies have also found an association between the receipt of antibiotics and an increased incidence of psychiatric disorders, perhaps due to alterations in the microbiome. Studies to characterize the intestinal microbiome of individuals with these disorders are in progress. The ultimate test of the role of the microbiome and immune-mediated pathology in schizophrenia and bipolar disorder will come from clinical trials of therapeutic agents which alter gut microbiota or gastrointestinal inflammation. The successful development of such modalities would represent a novel strategy to prevent and treat serious psychiatric disorders.”
In The News
News articles exploring relevant topics.